Patents by Inventor Huibin Tang

Huibin Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
    Patent number: 10240145
    Abstract: The invention relates to a clustered regularly interspaced short palindromic repeats (CRISPR)/Cas guide RNA (gRNA) comprising a targeting domain that is complementary to human genomic Epidermal Growth Factor Receptor (EGFR) DNA, and a vector system including one or more packaged vector(s) including: (a) a first regulatory element operably linked to a gRNA, and (b) a second regulatory element operably linked to a nucleic acid encoding a Cas protein. Also disclosed are methods of altering a nucleic acid sequence encoding EGFR in a cell including contacting the cell with a vector system, methods of treating lung cancer, and methods of selectively inducing apoptosis in a cell including administering a gRNA to the cell.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 26, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Huibin Tang, Joseph B. Shrager
  • CRISPR/CAS-MEDIATED GENOME EDITING TO TREAT EGFR-MUTANT LUNG CANCER
    Publication number: 20170145405
    Abstract: The invention relates to a clustered regularly interspaced short palindromic repeats (CRISPR)/Cas guide RNA (gRNA) comprising a targeting domain that is complementary to human genomic Epidermal Growth Factor Receptor (EGFR) DNA, and a vector system including one or more packaged vector(s) including: (a) a first regulatory element operably linked to a gRNA, and (b) a second regulatory element operably linked to a nucleic acid encoding a Cas protein. Also disclosed are methods of altering a nucleic acid sequence encoding EGFR in a cell including contacting the cell with a vector system, methods of treating lung cancer, and methods of selectively inducing apoptosis in a cell including administering a gRNA to the cell.
    Type: Application
    Filed: November 23, 2016
    Publication date: May 25, 2017
    Inventors: Huibin Tang, Joseph B. Shrager
  • Methods for treating denervation-induced muscle atrophy
    Patent number: 9511057
    Abstract: The present invention provides methods for the treatment of denervation-induced skeletal muscle atrophy, and generally, denervation-induced skeletal muscle degeneration diseases using agents that decrease the activity of mammalian target of rapamycin and/or the activity of at least one of the Forkhead Box Transcription Factors 1, 3 and 4.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 6, 2016
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Huibin Tang, Joseph Shrager
  • METHODS FOR TREATING DENERVATION-INDUCED MUSCLE ATROPHY
    Publication number: 20140275228
    Abstract: The present invention provides methods for the treatment of denervation-induced skeletal muscle atrophy, and generally, denervation-induced skeletal muscle degeneration diseases using agents that decrease the activity of mammalian target of rapamycin and/or the activity of at least one of the Forkhead Box Transcription Factors 1, 3 and 4.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Huibin Tang, Joseph Shrager